90 related articles for article (PubMed ID: 16925492)
1. MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma.
Hu XF; Yang E; Li J; Xing PX
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1261-71. PubMed ID: 16925492
[TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of new molecular targets for ovarian cancer.
Hu XF; Xing PX
Curr Opin Mol Ther; 2003 Dec; 5(6):625-30. PubMed ID: 14755889
[TBL] [Abstract][Full Text] [Related]
3. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
4. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene.
Wei X; Xu H; Kufe D
Cancer Res; 2007 Feb; 67(4):1853-8. PubMed ID: 17308127
[TBL] [Abstract][Full Text] [Related]
5. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells.
Singh PK; Wen Y; Swanson BJ; Shanmugam K; Kazlauskas A; Cerny RL; Gendler SJ; Hollingsworth MA
Cancer Res; 2007 Jun; 67(11):5201-10. PubMed ID: 17545600
[TBL] [Abstract][Full Text] [Related]
7. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.
Terry KL; Titus-Ernstoff L; McKolanis JR; Welch WR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):30-5. PubMed ID: 17220329
[TBL] [Abstract][Full Text] [Related]
8. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression.
Zaretsky JZ; Barnea I; Aylon Y; Gorivodsky M; Wreschner DH; Keydar I
Mol Cancer; 2006 Nov; 5():57. PubMed ID: 17083744
[TBL] [Abstract][Full Text] [Related]
9. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.
Duraisamy S; Ramasamy S; Kharbanda S; Kufe D
Gene; 2006 May; 373():28-34. PubMed ID: 16500040
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
12. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma.
Cloosen S; Gratama J; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; von Mensdorff-Pouilly S; Tarp MA; Mandel U; Clausen H; Germeraad WT; Bos GM
Br J Haematol; 2006 Nov; 135(4):513-6. PubMed ID: 17010104
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the human MUC1 oncoprotein.
Duraisamy S; Kufe T; Ramasamy S; Kufe D
Int J Oncol; 2007 Sep; 31(3):671-7. PubMed ID: 17671696
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy.
Singh AP; Chaturvedi P; Batra SK
Cancer Res; 2007 Jan; 67(2):433-6. PubMed ID: 17234748
[TBL] [Abstract][Full Text] [Related]
15. RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
Wang Q; Li M; Wang Y; Zhang Y; Jin S; Xie G; Liu Z; Wang S; Zhang H; Shen L; Ge H
Cancer Lett; 2008 Sep; 269(1):127-38. PubMed ID: 18534745
[TBL] [Abstract][Full Text] [Related]
16. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).
Sodek KL; Evangelou AI; Ignatchenko A; Agochiya M; Brown TJ; Ringuette MJ; Jurisica I; Kislinger T
Mol Biosyst; 2008 Jul; 4(7):762-73. PubMed ID: 18563251
[TBL] [Abstract][Full Text] [Related]
17. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1.
Shen Q; Rahn JJ; Zhang J; Gunasekera N; Sun X; Shaw AR; Hendzel MJ; Hoffman P; Bernier A; Hugh JC
Mol Cancer Res; 2008 Apr; 6(4):555-67. PubMed ID: 18403635
[TBL] [Abstract][Full Text] [Related]
18. MUC1 alters oncogenic events and transcription in human breast cancer cells.
Hattrup CL; Gendler SJ
Breast Cancer Res; 2006; 8(4):R37. PubMed ID: 16846534
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.
Chien JR; Aletti G; Bell DA; Keeney GL; Shridhar V; Hartmann LC
J Cell Biochem; 2007 Dec; 102(5):1117-29. PubMed ID: 17879946
[TBL] [Abstract][Full Text] [Related]
20. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase.
Mariette C; Piessen G; Leteurtre E; Hémon B; Triboulet JP; Van Seuningen I
Surgery; 2008 Jan; 143(1):58-71. PubMed ID: 18154934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
